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Relatively sparse literature developed during the past 30 years that 
sought to characterize the relationship of rheumatoid arthritis to 
neoplasms. The past decade has seen added concern over possible 
oncogenic effects of cytotoxic agents now used to manage some 
patients with rheumatoid arthritis. Acquisition of unambiguous data 
is complicated by the fact that the cumulative incidence of cancer in 
the general population exceeds 30 percent, and that most studies 
have insufficient patient numbers, duration follow-up, and attention 
to age, sex, race, or known etiologic agents. Thus, it is not surpris- 
ing to find reports that cancer incidence is high, low, or unchanged 
in rheumatoid arthritis. Although equally ambiguous data were ac- 
cumulated concerning potential neoplasm-inducing effects of cyto- 
toxic drugs, concern is justified in relation to increased frequency of 
bladder cancer after cyclophosphamide and acute leukemia follow- 
ing alkylating agents. 
The practice of administering cytotoxic drugs for the management of ac- 
tive rheumatoid arthritis unresponsive to conservative management or 
conventional forms of remittive therapy has been attended by increasing 
concern over the possibility that this form of therapy increases the fre- 
quency of malignancy in the rheumatoid patient population. Interest in 
this problem has been fueled by well-controlled studies describing the 
oncogenic properties of cyclophosphamide in NZB/NZW mice [I] in addi- 
tion to many anecdotal reports describing development of neoplasms in 
patients with rheumatoid arthritis following cytotoxic therapy. An essential 
component in the data base needed to evaluate the relative risk of using 
cytotoxic agents in nonlethal diseases, such as rheumatoid arthritis, in- 
cludes a clear perception of the “basal rate” or neoplasm development 
that might be anticipated in a population of patients with rheumatoid ar- 
thritis not treated with cytotoxic agents. Such information is essential to 
the unambiguous interpretation of outcomes related to neoplasms occur- 
ring in patients receiving cytotoxic agents. The frequent occurrence of 
circulating immune complexes in rheumatoid arthritis and neoplastic dis- 
eases is well recognized and has been extensively reviewed [2,3]. 
In rheumatoid arthritis, the immune complexes may play a pathoge- 
netic role in the ongoing tissue destruction caused by the inflammatory 
process. In neoplasms, circulating immune complexes appear to reflect 
tumor growth and dissemination. The precise role(s) of immune com- 
plexes in the course of neoplastic diseases is yet unclear. Although a 
polyarthritis, superficially resembling rheumatoid arthritis, has been de- 
scribed as an early manifestation of various malignancies, a careful study 
of one case failed to detect immune complex deposition in the synovial 
membrane [4]. 
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Figure 7. Average annual age-specific incidence rates per 
100,000 population by race and sex, SEER Program, all 
areas combined, 1973-1977. (Reprinted with permission 
from [5].) 
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Figure 2. Average annual age-specific incidence rates per 
100,000 population among white males (solid circles) and 
white females (open circles) in the United States. (Re- 
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Figure 3. Age-specific incidence rates for female breast 
cancer in four population groups. (Reprinted with permis- 
sion from [7].) 
Epidemiologic studies suggest that rheumatoid arthritis 
affects about 1 percent of the population, and although the 
disease may appear at any age, the peak ages of onset 
include the decade from age 35 to 45. Showing a change 
in the frequency of neoplasms occurring in such a popula- 
tion of patients with rheumatoid arthritis must take into 
account the high cumulative frequency of neoplasms in 
the general population, in which the cumulative incidence 
up to age 74 is approximately 26 percent in females in the 
United States, and 35 percent in males. As one can see in 
Figure 1, the age-specific incidence rates for neoplasms 
do not describe a linear course beginning with birth. In- 
stead, the incidence of neoplasms begins an exponential 
ascent at about the age when patients with rheumatoid 
arthritis begin to accumulate. To further compound the 
problem, it is apparent that the exponents are not the 
same for males and females [5]. From this curve, one 
might anticipate that careful follow-up of women beginning 
at age 50 would disclose a cumulative incidence of about 
3.3 percent after five years, 8.8 percent after 10 years, 
and 14.4 percent after 15 years. Some neoplasms of spe- 
cial concern to the present discussion show an age-spe- 
cific incidence curve unlike the “all sites” curve in Figure 
1. Non-Hodgkin’s lymphoma (Figure 2) has an age-spe- 
cific incidence rate starting in the first decade of life and 
rising dramatically in linear fashion over the usual life 
span. Between age 40 and 60, the age-specific incidence 
increases from three to 15 per 100,000 [6]. Not only is it 
important to control for age and sex, but, as shown in Fig- 
ure 3, with particular tumor types-in this case breast 
cancer-racial, ethnic, and possibly dietary or environ- 
mental factors may contribute significantly to the age-spe- 
cific incidence of neoplasms [7]. 
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Compilation of data related to the association of rheu- 
matoid arthritis and neoplasms will necessarily be re- 
stricted to more recent decades, since rheumatoid arthritis 
has been diagnosed with reasonable certainty since about 
1940, and generally accepted criteria for the diagnosis of 
this disease have only been available since 1958. 
TABLE I Causes of Death in Patients with 
Rheumatoid Arthritis 




One of the earliest studies of the frequency of cancer in 
patients with rheumatoid arthritis was an investigation of 
the major causes of death in a series of 583 patients with 
rheumatoid arthritis hospitalized at the Massachusetts 
General Hospital and followed for an average of nearly IO 
years. It was of interest that the notable causes of death at 
that time were valvular heart disease, infection, renal dis- 
ease, and pulmonary embolism [8]. These data suggested 
that patients with rheumatoid arthritis had a higher mortal- 
ity rate than did the general population, due mainly to the 
fact that younger patients died earlier; the longevity of pa- 
tients over 50 was not altered. In this group of 583 pa- 
tients, 130 died and the cause of death was determined 
(Table I). Cancer accounted for 11.5 percent of the deaths 
in this selected population of patients with rheumatoid ar- 
thritis. The authors compiled the observations of several 
autopsy series, including their own, and noted that in this 
accumulated autopsy series of patients with rheumatoid 
arthritis, cancer was the cause of death in 7 percent of the 
191 patients. Interestingly, a later report of autopsy statis- 
tics from Finland noted three neoplasms (7 percent) in 41 
patients with rheumatoid arthritis in whom the cause of 













of Total Number of Total 
11.5 14 7 
24.6 35 19 
24.6 82 41 
13.0 21 11.5 
accident 
Gastrointestinal 
12 9.2 4 2 
disease 8 6.1 11 5.5 
Pulmonary embolism 4 3.1 12 7 
Accident 0 0 1 0.5 
Miscellaneous 10 7.7 11 6 
Total 130 191 
Modified from [8]. 
CLINICAL DATA MEASURING FREQUENCY 
OF CANCER 
subsequent neoplasm was noted compared with a large 
population of patients with benign essential hypertension 
studied in a similar manner (Table Ill) [IO]. In summary, 
these data provide little evidence among United States 
population groups to suggest major differences in the fre- 
quency of cancer in patients known to have rheumatoid 
arthritis. Furthermore, the distribution of neoplasms ap 
pears to reflect the profile seen in the general population. 
Unfortunately, these studies in general have not been cor- 
rected for the relative risks presented by other known etio- 
logic agents and, sometimes, have not been corrected for 
race, sex, or cumulative incidence rates reflecting the real 
risk of the population groups. 
Several reports have assessed the frequency of cancer in Although the frequency of lymphoma in “garden vari- 
patients with rheumatoid arthritis, and these data are ety” rheumatoid arthritis does not seem to be clearly in- 
shown in Table II. Such studies clearly do not raise a creased, recent data suggest that. the risk of lymphoma 
major suspicion that neoplasm frequency in patients with may be increased in those patients with Sjogren’s syn- 
rheumatoid arthritis differs greatly from the general popu- drome and rheumatoid arthritis [II]. Among 136 women 
lation. In another study of 2,857 patients with rheumatoid with sicca syndrome, non-Hodgkin’s lymphoma devel- 
arthritis admitted to hospital, an unexpectedly low rate of oped in seven from six months to 13 years following initial 
NEOPLASMS IN RHEUMATOID ARTHRITIS-CASTOR and BULL 
TABLE II Frequency of Neoplasms in Patients with Rheumatoid Arthritis 
Reference 
Years of Number of 
Follow-up Patients 
Control Rheumatoid Arthritis 
Neoplasms Neoplasms 
Number of 
Number Percent Patients Number Percent 
WI >4* 125 5 4 196 8 4.1 
WI 5 -t - * 374 - 2 
I171 4.7-4.9 126 9 7 126 9 7 
*Range = one to 288 months. 
+No explicit data. 
*Believed to be similar to patients with rheumatoid arthritis in whom neoplasms developed. 
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Female Male Female Number Percent 
Statistical 
Significance+ 
Benign essential hypertension 3,295 49 45.7 + 13.4 44.2 2 12.7 44 1.36 - 
Rheumatoid arthritis 2,867 64 47.1 ‘-c 18.2 46.4 ? 17 17 0159 p co.005 
Discoid lupus erythematosus 253 68 42.6 f 15.2 39.6 2 14.7 4 i .58 p >0.70 
Systemic lupus erythematosus 484 83 38.3 k 18.4 33.8 ? 15.3 18 3.72 p <0.0005 
*The racial breakdown for the primary diagnosis for whites and blacks, respectively, was: hypertension, 82 and 18 percent; rheumatoid arthritis, 94 
and 6 percent; discoid lupus erythematosus, 87 and 13 percent; and systemic lupus erythematosus, 86 and 14 percent. 
+Computed by chi-square analysis. 
Modified from [lo]. 
assessment, a rate approximately 44 times the incidence 
expected on the basis of cancer rates prevailing among 
women of the same age in the general population. The 
frequency of cancers other that-i lymphoma was similar to 
that found among the general population. The risk for pa- 
tients with the sicca syndrome including rheumatoid ar- 
thritis was the same as that for patients having sicca syn- 
drome without rheumatoid arthritis. 
STUDIES EVALUATING THE INFLUENCE OF 
CYTOTOXICAGENTSONTHE FREQUENCYOF 
CANCER 
Clinical trials with cyclophosphamide terid to support the 
concept that this drug suppresses the activity of rheuma- 
toid arthritis, although treatment is frequently accompa- 
nied by hemorrhagic cystitis, amenorrhea, alopecia, and 
gastrointestinal symptoms [12-141. In a study of 88 pa- 
tients with active rheumatoid arthritis evaluated by the 
Cooperating Clinics during a 32-week controlled, double- 
blind trial, 75 and 150 mg of cyclophosphamide daily led 
to improvement of arthritis with few important differences 
between the two treatment groups [15]. The lower dose 
was associated with less leukopenia and alopecia. In the 
TABLE IV Causes df Death in Patients with 
Rheumatoid Arthritis Treated with 
Cytotoxic Agents 
Treatment 
Conventional Cytotoxic Agents 
(n = 141) (n = 28) 
Cause of Death Number Percent Number Percent 
Neoplasms -* 6 8 28.5 
Infections - 29 8 28.5 
Cardiovascular accident - 14 0 - 
Cardiopulmonary disease - 28 7 25 
Miscellaneous j - 23 5 18 
*No explicit data. 
Modified from [16]. 
context of these controlled trials, usually lasting a year or 
less, which imply that cyclophosphamide is a therapeuti- 
cally useful agent, it is important to attempt to examine the 
long-term risk of subsequent neoplasms. Although anec- 
dotal data tend to raise considerable alarm over the possi- 
ble cancer-inducing influence, few unambiguous con- 
trolled data are available. 
An early preliminary report focused attention on the 
possible oncogenic properties of cytotoxic agents used for 
treatment of rheumatoid arthritis. This showed four to five 
times the frequency of neoplasms as a cause of death in 
28 patients’treated with these agents as was seen in 141 
patients treated with conventional regimens [16] (Table 
IV). In the cytotoxic-treated groups, seven of the eight pa- 
tients with neoplasms had a lymphoproliferative disease. 
A group of 126 patients with rheumatoid arthritis admit- 
ted to the hospital between the years 1965 to 1974 was 
treated with cytotoxic drugs and compared with an age- 
and sex-matched population of patients with rheumatoid 
arthritis. The follow-up period was approximately five 
years for each group [17]. The frequency of neoplasms 
before the study in these patients was five of 126 patients 
in the control group and seven of 126 in the group subse- 
quently treated with cytotoxic agents. During the follow-up 
period, each group showed the developnient of nine neo- 
plasms, including one lymphoma in the control group (Ta- 
bles V and VI). 
DEVELOPMENT OF ACUTE LEUKEMIA IN PATIENTS 
TREATED WITH CYTOTOXIC AGENTS 
An early repot-l described two patients with rheumatoid 
arthritis treated with cyclophosphamide in whom acute 
leukemia developed; both had also been treated with 
long-term azathioprine. The authors reviewed four addi- 
tional cases of acute leukemia following cytotoxic drug 
therapy for rheumatoid arthritis [18]. A subsequent case 
report suggested that acute myelogenous leukemia de- 
veloped in a patient with rheumatoid arthritis ,related to 
cyclophosphamide treatment (25 mg per day) over a 
four-year period [19]. Acute myelomonocytic leukemia 
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was reported in a patient with rheumatoid arthritis 
and Sj8gren’s syndrome following 31 months of cyclo- 
phosphamide therapy [20]. It is pertinent to note that 
this patient had been treated previously with gold, 
hydroxychloroquine, and methotrexate before initiation of 
treatment with cyclophosphamide. The authors point out 
that although patients with Sjiigren’s syndrome are known 
to have an increased risk of development of proliferative 
disorders, particularly reticulum cell sarcoma, acute leu- 
kemia is distinctly unusual. 
DEVELOPMENT OF CARCINOMA OF THE BLADDER 
In a population of 54 patients treated with cyclophospha- 
mide (11 with rheumatoid arthritis, 43 with systemic lupus 
erythematosus), two cases of bladder carcinoma were 
reported: one in each disease group [21]. Bladder carci- 
noma developed 28 to 60 months after withdrawal of the 
drug; one of the two victims smoked cigarettes. Since the 
expected number of cases of bladder carcinoma based on 
the age incidence for that locale was 0.02 for the period of 
observation, and the actual number of cases was two of 
54 patients, the relative risk ratio was thought to be ap- 
proximately 100. Carcinoma of the bladder was also re- 
ported in a 75-year-old woman (a nonsmoker) treated with 
a maximum of 50 mg per day of cyclophosphamide over a 
period of about 12 years [22]. 
DATA DERIVED FROM CANCER CHEMOTHERAPY 
Cancer chemotherapists have become concerned over 
the likelihood of development of a second neoplasm as a 
complication of cancer chemotherapy. A review of this 
problem pointa out that alkylating agents used to treat 
ovarian cancer, Hodgkin’s disease, and as an adjuvant in 
the treatment of breast cancer have been associated with 
apparent excess development of acute leukemia [23]. The 
data appear to indicate that, in humans, a four-year latent 
period may be expected from the initiation of drug expo- 
sure until the appearance of the second neoplasm. 
Difficulties inherent in interpreting this sort of data may 
be appreciated by considering one of these studies [24]. 
In this study, the leukemogenic potential of alkylating 
agents used for the treatment of patients with advanced 
ovarian cancer was examined. Thirteen cases of acute 
nonlymphocytic leukemia occurred among 5,455 patients 
compared with the 0.62 cases expected, yielding a rela- 
tive risk of approximately 21. Although all 13 patients in 
whom leukemia developed received alkylating agents, 
nine had also received radiotherapy. The authors referred 
to another study involving over 13,000 patients with ovar- 
ian cancer in which no excess of leukemia was noted, 
even among a large number who also received radiation. 
Consequently, although the excess may be attributable to 
alkylating agents, it is difficult to exclude the possibility 
that these effects were magnified by exposure to radia- 
tion. 
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TABLE V Cytotoxic Drugs and Neoplasms in 
Patients with Rheumatoid Arthritis 
Neoplasms 
Age-sex matched 
Number Before Study During Study 
rheumatoid arthritis 
control group 126 5 9 
Cytotoxic-treated* 
rheumatoid arthritis 
group 126 7 9 
Follow-up = 4.7 to 4.9 years. 
*Cytotoxic drugs = cyclophosphamide and/or nitrogen mustard 
(105), remainder received one or both with chlorambucil, thiotepa, 
methotrexate, or azathioprene. 
From [17]. 
TABLE VI Types of Neoplasms in Patients with 
Rheumatoid Arthritis 
Type of Cancer Control Subjects Cytotoxic-Treated Patients 
Basal cell carcinoma 3 4 
Breast 3 - 
Lung 1 3 
Carcinomatosis 1 1 
Lymphoma 1 - 
Gastric - 1 
Modified from [17]. 
A nine-fold increase in bladder cancer was found in pa- 
tients who were treated with cyclophosphamide for an ini- 
tial non-uroepithelial cancer [25]. Among 19,082 patients 
examined who survived the non-uroepithelial cancer for at 
least five years, bladder cancer, as a second neoplasm, 
developed in 42. In terms of treatment, 170 patients had 
been treated with cyclophosphamide for their primary 
neoplasm, and among this group, bladder cancer, as a 
second neoplasm, developed in three (1.8 percent), 
whereas only 39 patients, among the 18,912 not treated 
with cyclophosphamide, had bladder cancer (0.21 per- 
cent). Interestingly, the three patients in whom bladder 
cancer developed following cyclophosphamide therapy 
were, in fact, long-term survivors of non-urologic cancers 
and, in addition, had a long cigarette-smoking history. Two 
had received substantial doses of abdominal/pelvic radia- 
tion in the treatment of their first tumor. Clearly, it is diffi- 
cult to interpret such data in an unambiguous fashion. 
COMMENTS 
Review of the data in the United States related to the fre- 
quency of neoplasms in rheumatoid arthritis subsets of 
the population and possible oncogenic effects of cytotoxic 
drug therapy used for rheumatoid arthritis does not en- 
courage very firm conclusions. Available data do not 
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make a case for an unusual cancer incidence in patients 
with rheumatoid arthritis. This is further weakened by rec- 
ognition that available data are meager and flawed by in- 
clusion of uncontrolled variables discussed earlier. Con- 
cern over possible cyclophosphamide induction of bladder 
cancer and acute leukemia promoted by alkylating agents 
is justified. This is not to say that these relationships are 
proved beyond reasonable doubt or that the magnitude of 
the risk has been quantified. Definitive data will probably 
require an extended longitudinal study of a very large 
group of patients in order to permit adequate stratification 
and control of complicating variables. 
Aggressive, mutilating, incapacitating rheumatoid ar- 
thritis, uncontrolled by conventional therapy, presents its 
own set of risks. Many patients and physicians may con- 
clude that the personal consequences of uncontrolled 
rheumatoid arthritis outweigh the additional risks that may 
be inherent in cytotoxic therapy. Clearly, patients must 
understand this “balance of risks” before accepting cyto- 
toxic therapy for rheumatoid arthritis. 
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